Tag:

Revlimid

Latest Headlines

Latest Headlines

Celgene buries the hatchet with India's Natco over generic Revlimid

Celgene is getting in the holiday spirit, settling the score with Indian generics maker Natco over patents for its cancer blockbuster Revlimid. 

Celgene opens door for early launch of Revlimid generics

Just in time for the holidays, Celgene settled the score with Natco Pharma over patents for its cancer blockbuster Revlimid. The company is allowing the Indian generics maker to start selling copycat versions of its best-selling drug before Revlimid goes completely off patent in 2027, but with a few strings attached.

Patent challenger Bass wins IP reviews for Celgene, Shire meds

Chalk up a win for pharma patent challenger Kyle Bass. The U.S. Patent and Trademark Office has agreed to institute trials for 6 of the drug patents he's challenged--and IP shields for Celgene's Revlimid and Shire's Gattex are among them.

FDA grants Celgene's Revlimid new use as it moves toward $10B in sales

Celgene's powerhouse cancer drug Revlimid generated nearly $5 billion for the company last year and has now gotten yet another FDA nod which analysts believe will help it double that amount within 5 years.

New Celgene meds power forward, but Revlimid's still the Big Kahuna

Celgene edged past analyst estimates for the fourth quarter and full year, with earnings of $3.71 per share and $7.67 billion in revenue for 2014. Its powerhouse remedy for multiple myeloma, Revlimid, still accounts for the lion's share of those sales, at $4.98 billion in 2014 revenue, an increase of 16%.

Celgene's powerhouse Revlimid gets a little Q3 help from new friends Pomalyst, Otezla

Celgene's growth engine Revlimid came through again this quarter. The blood cancer drug's $1.3 billion in Q3 sales--a 19% increase--helped the company hit sales estimates and beat profit expectations. And if a new first-line indication wins FDA approval, expected soon, the drug could take another leap next year.

Celgene's cost-sharing offer persuades NICE to about-face on Revlimid

Celgene used a tried-and-true technique to persuade cost-effectiveness watchdogs to change their minds on Revlimid. The U.S.-based drugmaker capped its cost.

Celgene cost-sharing deal sways NICE to greenlight new Revlimid use

Celgene used a tried-and-true technique to persuade cost-effectiveness watchdogs to change their minds on Revlimid. The U.S.-based drugmaker capped its cost.

Amgen preps for swift FDA review as Kyprolis/Revlimid combo stymies myeloma

Amgen put out the word Monday morning that Kyprolis--provided in a combo package with Celgene's Revlimid--beat out Revlimid alone in a head-to-head Phase III study for multiple myeloma, hitting the primary endpoint and offering the Big Biotech a shot at expanding its franchise for the drug at a critical moment in the company's history.

Judge refuses to toss off-label Revlimid marketing lawsuit against Celgene

Thanks to a recent court ruling, a former Celgene sales rep's off-label marketing lawsuit will go forward. The rep, Beverly Brown, claims the company pushed its multiple myeloma drugs Thalomid and Revlimid for uses not approved by the FDA--and a judge says she's produced enough evidence to justify a trial.
'